Cozaar contains losartan potassium, an angiotensin II receptor antagonist for adults with high blood pressure and selected kidney complications from type 2 diabetes. By blocking angiotensin II receptors, it relaxes blood vessels, lowers vascular resistance, and reduces strain on the heart and kidneys.
Cozaar contains losartan potassium, an angiotensin II receptor antagonist for adults with high blood pressure and selected kidney complications from type 2 diabetes. By blocking angiotensin II receptors, it relaxes blood vessels, lowers vascular resistance, and reduces strain on the heart and kidneys.
Cozaar tablets are taken by mouth, usually once daily. The prescribed dose differs between strengths and between users, so there is no single amount suitable for everyone.
Doctors may begin with a lower dose in people who are dehydrated, taking strong diuretics, or vulnerable to a sudden fall in blood pressure. The dose may be increased after reviewing blood-pressure readings, kidney function, and serum potassium.
For diabetic nephropathy, treatment commonly involves gradual adjustment toward the dose that provides renal and blood-pressure benefit without unacceptable hypotension or potassium elevation. The appropriate regimen must be individualised.
Do not stop Cozaar suddenly without a treatment plan. Blood pressure may rise again when antihypertensive therapy is interrupted, even if no symptoms appear.
Cozaar contains losartan potassium, the potassium salt of losartan. Losartan belongs to the angiotensin II receptor antagonist class, also called angiotensin receptor blockers or ARBs. The medicine is used mainly for hypertension and for kidney protection in adults with type 2 diabetes and protein loss through the kidneys.
Losartan is the generic name associated with the active substance. Cozaar is the product name used for tablets containing losartan potassium.
Angiotensin II is a hormone that narrows blood vessels and stimulates aldosterone release. Aldosterone encourages the kidneys to retain sodium and water, which can increase blood volume and blood pressure.
Losartan blocks the angiotensin II type 1 receptor. Blood vessels can then relax, aldosterone activity falls, and pressure against arterial walls decreases. The kidneys also experience less pressure-related injury.
The mechanism differs from an angiotensin-converting enzyme inhibitor because losartan blocks the receptor directly rather than preventing angiotensin II formation. This distinction helps explain why losartan is often selected when an ACE inhibitor causes a persistent cough.
Health Canada and the European Medicines Agency recognise losartan as an ARB used in blood-pressure management and selected cardiovascular or renal indications [1].
Cozaar is prescribed for adults whose blood pressure requires treatment. It may also be used to reduce kidney deterioration in adults with type 2 diabetes, hypertension, and diabetic nephropathy.
| Clinical use | Main treatment goal | Typical patient group |
|---|---|---|
| Hypertension | Lower arterial blood pressure | Adults with persistent high blood pressure |
| Diabetic nephropathy | Reduce pressure-related kidney stress and proteinuria | Adults with type 2 diabetes and kidney involvement |
| Cardiovascular risk reduction | Reduce strain linked with uncontrolled pressure | Selected adults requiring ARB therapy |
Blood pressure often improves before a person feels any different. Hypertension can remain symptomless for years, so treatment decisions rely on measured readings, kidney results, potassium levels, and the person’s wider cardiovascular risk.
Losartan may be used alone or alongside other blood-pressure medicines. The selected regimen depends on the starting pressure, kidney function, age, hydration status, and response over time.
The kidney indication is more specific than general blood-pressure treatment. A person with type 2 diabetes does not automatically need Cozaar; the renal indication relates to documented hypertension and diabetic kidney disease.
The World Health Organization identifies blood-pressure control as a major strategy for reducing stroke, heart disease, and kidney complications [2].
Several everyday errors can make Cozaar appear less helpful or increase avoidable risk.
Home readings are most useful when taken under similar conditions. Rest quietly before measuring, keep the arm supported, and record repeated readings rather than reacting to one isolated result.
Losartan potassium is not suitable for people with hypersensitivity to losartan or any component of the prescribed product. A previous episode of swelling involving the face, lips, tongue, or airway after an ARB requires careful clinical review before another ARB is considered.
Cozaar is not for you if:
Extra caution is needed with renal artery narrowing, chronic kidney disease, heart failure, dehydration, severe liver impairment, or a history of angioedema. These conditions can alter blood-pressure response or increase the risk of kidney-function changes and potassium elevation.
Cozaar may reduce blood pressure too far when combined with intensive diuretic treatment or other antihypertensive medicines. A clinician may monitor blood pressure more closely during initiation or dose changes.
Talk to a clinician before using Cozaar if you have had swelling of the face, lips, tongue, or airway after taking an ARB. Pregnancy, diabetes or reduced kidney function while taking aliskiren, severe dehydration, unstable blood pressure, and significant kidney or liver disease require medical assessment rather than self-treatment.
Losartan is tolerated by many adults, yet adverse effects remain possible. Dizziness, fatigue, headache, and upper respiratory symptoms are among the reactions reported during treatment. Dizziness is more likely when therapy begins, after a dose increase, or when fluid intake has been reduced.
Common or clinically recognised effects can include:
Many reactions are mild and may settle as the body adjusts. Persistent weakness, palpitations, marked muscle symptoms, or unusual tingling can signal potassium disturbance and require prompt medical assessment.
Rare but serious reactions include angioedema, severe allergic response, marked hypotension, kidney-function deterioration, and significant hyperkalemia. Angioedema may cause swelling of the lips, tongue, face, or throat and needs urgent medical attention.
One practical detail is easy to miss: a person can have dangerously high potassium without feeling unwell. Blood testing matters more than symptoms when losartan is combined with kidney disease, potassium supplements, or potassium-sparing treatment.
Another useful point concerns cough. Losartan can cause cough, but cough is generally less characteristic than with ACE inhibitor therapy. A cough that began during a previous ACE inhibitor treatment does not guarantee that losartan will cause the same problem.
Health Canada’s product information describes hypotension, renal effects, potassium elevation, and hypersensitivity as clinically relevant safety issues [3].
Cozaar is an oral, single-ingredient treatment that lowers blood pressure by blocking angiotensin II receptors. Its use differs by treatment goal: it may address hypertension or reduce kidney deterioration in selected adults with type 2 diabetes, hypertension, and diabetic nephropathy.
In clinical practice, doctors usually judge Cozaar by measured blood pressure, kidney results, potassium, and treatment tolerability rather than by symptoms alone. A person may feel well while pressure remains above target.
The first review often focuses on dizziness, falls risk, hydration, and the medicines already being taken. Follow-up blood tests may be used after initiation or dose changes, especially when kidney disease, diabetes, or potassium-raising treatment is present.
Doctors also distinguish between two goals: reducing blood pressure and protecting kidney function. Those goals can overlap, yet the monitoring plan may differ. A useful response includes controlled readings without excessive hypotension, worsening kidney function, or hyperkalemia.
Losartan does not remove the need for lifestyle measures. Sodium reduction, appropriate physical activity, smoking cessation, weight management, and treatment of diabetes can all influence cardiovascular risk.
Potassium supplements, potassium-based salt substitutes, amiloride, and triamterene can increase the risk of hyperkalemia with losartan. ACE inhibitors and aliskiren can add kidney and blood-pressure effects when combined with an ARB. Health Canada’s losartan information, reviewed in 2022, supports checking kidney function and potassium when clinically indicated. The WHO also identifies combination renin–angiotensin blockade as a treatment area requiring careful selection and monitoring. A clinician can determine whether additional monitoring is needed.
Cozaar is often used as ongoing treatment because hypertension and diabetic kidney disease are chronic conditions. The course may continue for months or years when blood pressure, kidney function, and potassium remain suitable. NICE guidance reviewed in 2023 describes antihypertensive therapy as long-term care adjusted to response and tolerability. Treatment should not be stopped solely because readings improve, since the improvement may reflect the medicine’s continuing action.
Cozaar blocks angiotensin II receptors, while ACE inhibitors reduce the formation of angiotensin II. Both approaches lower vascular resistance and reduce aldosterone-driven sodium retention, yet their adverse-effect patterns differ. The EMA’s losartan product information from 2024 describes cough as a recognised concern with renin–angiotensin medicines, with cough often associated more strongly with ACE inhibitor treatment. Choice depends on clinical history, kidney status, potassium, pregnancy potential, and prior tolerability.
Dizziness can occur, especially after starting treatment, increasing the dose, becoming dehydrated, or combining several blood-pressure medicines. The FDA’s losartan prescribing information from 2023 lists dizziness and hypotension among recognised reactions. Sit or lie down if light-headedness develops, avoid driving until the symptom passes, and seek urgent help for fainting, severe weakness, or swelling of the face or throat.
Losartan is designed for once-daily blood-pressure treatment, although the duration of control varies with the prescribed dose, kidney function, liver function, and individual metabolism. The active metabolite contributes to the blood-pressure effect after the parent drug is processed. The EMA assessment report from 2019 describes the pharmacokinetic basis for sustained antihypertensive activity across the dosing interval. Do not take an extra tablet because a single reading is higher than expected.
Cozaar can generally be taken with food or on an empty stomach. Food may affect absorption modestly, but the more useful habit is taking the tablet consistently at a similar time each day. Health Canada’s product monograph from 2022 permits administration without regard to meals. Take the tablet with water and avoid changing the routine repeatedly if stable blood-pressure readings depend on consistent timing.
Pregnancy is a specific condition that rules out routine Cozaar treatment because renin–angiotensin system blockade can harm fetal kidney development. The EMA’s 2024 product information states that ARBs should not be used during pregnancy, especially after the first trimester. Losartan is also unsuitable for people with hypersensitivity to its active ingredient or components, and aliskiren combinations require avoidance in diabetes or impaired kidney function.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I took Cozaar at the prescribed daily dose for several months. My home readings became much steadier, and I felt more confident during routine checks. The tablet fitted easily into my morning routine.
I used Cozaar for a short period but did not notice enough improvement in my readings. I also felt light-headed on some mornings, so I stopped and discussed a different approach with my doctor.
After taking the prescribed dose consistently, my readings were lower at my regular checks. I liked that the tablet could be taken with breakfast and did not interfere with my usual routine.
Cozaar gave me a more stable pattern over time. I kept the tablet beside my breakfast items, which helped me remember it, and I was satisfied with the improvement.
The treatment helped, but the effect was slower than I expected and I had occasional dizziness at first. My doctor reviewed the dose and the symptoms became easier to manage.
